Najafi M, Eskandarieh S, Rezaeemanesh N, Heydari H, Moosavi M, Harirchian M H. COVID-19 and its Outcomes in Multiple Sclerosis Patients. Caspian J Neurol Sci 2022; 8 (2) :98-103
URL:
http://cjns.gums.ac.ir/article-1-519-en.html
1- Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
2- Iranian Centre of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Abstract: (927 Views)
Background: Coronavirus Disease 2019 (COVID-19) is a highly contagious disease that
resulted in 4533645 deaths until September first, 2021. Multiple Sclerosis (MS) patients receive
immunosuppressive drugs. Thus, there is a concern that these drugs will reduce the patient’s
immune system resistance against COVID19.
Objectives: This study aimed to evaluate the epidemiology of COVID19 and its impact on MS
patients in our university hospital in Tehran City, Iran.
Materials & Methods: A cross-sectional study was conducted based on hospital-based registry
data from May 2020 to March 2021. Among more than 500 registered MS patients in Imam
Khomeini Hospital in Tehran City, Iran, referring within our study period, 84 patients reported
SARS-COV2 infection. The diagnosis of MS was confirmed by the McDonald criteria. Moreover,
the diagnosis of COVID-19 in MS patients was established by the real-time-PCR technique and
chest computed tomography.
Results: Out of 84 MS patients with SARS-COV2 infection, 55(65.5%) were women, and their
mean age was 37.48 years. The most commonly used medications by MS patients were Rituximab
20 (26.3%) and Dimethyl Fumarate 14(18.4%). Totally, 9(10.8%) of the patients needed to be
hospitalized due to COVID-19, with a mean hospitalization duration of 5.88 days. A total of 1
(1.2%) death was reported.
Conclusion: Compared to the healthy population, COVID-19 is not more serious in MS patients.
Most MS patients with COVID-19 infection were not hospitalized and continued their medication
during the infection.
Full-Text [PDF 1079 kb]
(345 Downloads)
| |
Full-Text (HTML) (310 Views)
• The most commonly used disease-modifying therapy among MS patients is Rituximab.
• Disease-modifying therapies did not have adverse outcomes during Coronavirus Disease 2019 (COVID-19) pandemic.
• The mortality rate of MS patients is not higher than the general population.
Type of Study:
Research |
Subject:
Special Received: 2022/04/6 | Accepted: 2022/04/21 | Published: 2022/04/21